MLNT - Melinta Therapeutics Inc.

0.5
0   0%

Share volume: 0
Last Updated: 01-10-2020

PREVIOUS CLOSE
CHG
CHG%
$0.50
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.50
P/E Ratio 
N/A
DAY RANGE
$0.50 - $0.50
EPS 
-$25.02
52 WEEK RANGE
$0.31 - $0.46
52 WEEK CHANGE
$0.00
MARKET CAP 
6.050 M
YIELD 
N/A
SHARES OUTSTANDING 
13.751 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$10,369,815
AVERAGE 10 VOLUME 
$1,107,248
AVERAGE 30 VOLUME 
$1,107,248
Company detail
CEO: Jennifer A. Sanfilippo
Region: US
Website: http://www.melinta.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:

Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.

Recent news